Evidence mapPaperPMID 42547601Full record

ArticleBasic research in cardiology2026

MiR-145-5p modulates collagen production and fibroblast behaviour after cardiac injury partially via COL5A1.

Hong Wang, Jere Paavola, Sanni Perttunen, Katariina Immonen, Ian Hägerström, Suneeta Narumanchi, Karri Kalervo, Johanna Tolva, Juha Sinisalo, Mikko I Mäyränpää and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in Basic research in cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Hong WangMinerva Foundation Institute for Medical Research, Biomedicum Helsinki 2U, Tukholmankatu 8, 00290, Helsinki, Finland. hong.wang@helsinki.fi.ORCID http://orcid.org/0000-0001-5700-6786
Jere PaavolaMinerva Foundation Institute for Medical Research, Biomedicum Helsinki 2U, Tukholmankatu 8, 00290, Helsinki, Finland.
Sanni PerttunenMinerva Foundation Institute for Medical Research, Biomedicum Helsinki 2U, Tukholmankatu 8, 00290, Helsinki, Finland.
Katariina ImmonenMinerva Foundation Institute for Medical Research, Biomedicum Helsinki 2U, Tukholmankatu 8, 00290, Helsinki, Finland.
Ian HägerströmMinerva Foundation Institute for Medical Research, Biomedicum Helsinki 2U, Tukholmankatu 8, 00290, Helsinki, Finland.
Suneeta NarumanchiMinerva Foundation Institute for Medical Research, Biomedicum Helsinki 2U, Tukholmankatu 8, 00290, Helsinki, Finland.
Karri KalervoMinerva Foundation Institute for Medical Research, Biomedicum Helsinki 2U, Tukholmankatu 8, 00290, Helsinki, Finland.
Johanna TolvaHeart and Lung Centre, University of Helsinki and Helsinki University Hospital, 00014, Helsinki, Finland.
Juha SinisaloHeart and Lung Centre, University of Helsinki and Helsinki University Hospital, 00014, Helsinki, Finland.
Mikko I MäyränpääDepartment of Pathology, University of Helsinki and Helsinki University Hospital, 00014, Helsinki, Finland.
Heikki RuskoahoDrug Research Program, Division of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of Helsinki, 00014, Helsinki, Finland.
Riikka KosonenMinerva Foundation Institute for Medical Research, Biomedicum Helsinki 2U, Tukholmankatu 8, 00290, Helsinki, Finland.
Vesa M OlkkonenMinerva Foundation Institute for Medical Research, Biomedicum Helsinki 2U, Tukholmankatu 8, 00290, Helsinki, Finland.
Mika LaineMinerva Foundation Institute for Medical Research, Biomedicum Helsinki 2U, Tukholmankatu 8, 00290, Helsinki, Finland.
Ilkka TikkanenMinerva Foundation Institute for Medical Research, Biomedicum Helsinki 2U, Tukholmankatu 8, 00290, Helsinki, Finland.
Päivi LakkistoMinerva Foundation Institute for Medical Research, Biomedicum Helsinki 2U, Tukholmankatu 8, 00290, Helsinki, Finland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In contrast to humans, zebrafish hearts after cryoinjury undergo transient fibrotic scarring that subsequently resolves and renews with functional cardiomyocytes. To understand the molecular mechanisms underlying cardiac scarring and fibrotic resolution in zebrafish, we investigated cardiac transcriptomic responses in zebrafish at 14 days post-cryoinjury. Principal component analyses revealed distinct transcriptome clusters corresponding to healthy and injured hearts, highlighting significant changes during cardiac regeneration. Gene set enrichment analyses indicated that extracellular matrix organization and inflammatory response pathways were activated in cryoinjured hearts, while mitochondrial organization and oxidative phosphorylation pathways were downregulated. Notably, miR-145-5p was downregulated and col5a1 upregulated in the cryoinjured hearts, contrasting with the expression patterns of miR-145-5p and COL5α1 in the left ventricles of ischemic cardiomyopathy patients. Prediction of miRNA-mRNA interaction and a dual luciferase assay identified COL5A1 as a target of miR-145-5p. Inhibition of miR-145-5p in human cardiac fibroblasts increased COL5A1 and α-SMA, decreased COL1A, and stimulated fibroblast differentiation, proliferation, and migration. Conversely, overexpression of miR-145-5p led to the opposite effects. Downregulation of COL5A1 suppressed fibroblast proliferation and migration, which could be rescued by inhibition of miR-145-5p. Moreover, downregulation of col5a1 attenuated cardiac fibrotic scar resolution in zebrafish. Interestingly, downregulation of COL5A1 or inhibition of miR-145-5p diminished the expression of integrin subunits ITGβ3 and ITGβ5. Furthermore, inhibition of miR-145-5p potentiated the suppression of TGF-β/SMAD signalling and the enhancement of fibroblast proliferation mediated by inhibiting integrin αvβ3 and αvβ5 with cilengitide. Collectively, miR-145-5p modulates collagen production and fibroblast behaviour partially via targeting COL5A1 and through integrin-mediated pathways.

Indexed as

Cardiac fibrosisCardiac scar resolutionCOL5A1MiR-145-5p

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.